Австралия - английски - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - moxifloxacin, quantity: 400 mg (equivalent: moxifloxacin hydrochloride, qty 436.8 mg) - tablet, film coated - excipient ingredients: titanium dioxide; microcrystalline cellulose; hypromellose; ferric oxide; croscarmellose sodium; lactose monohydrate; magnesium stearate; macrogol 400 - avelox (moxifloxacin hydrochloride) tablets are indicated for the treatment of adults with infections caused by susceptible organisms in the conditions. acute bacterial sinusitis, community acquired pneumonia, acute exacerbations of chronic bronchitis. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults who require initial iv therapy for the treatment of infections in the conditions. community acquired pneumonia (caused by susceptible organisms). acute exacerbations of chronic bronchitis when caused by organisms bacteriologically proven to be resistant to other classes of antibiotics or when there is intolerance to other antibiotics. avelox iv (moxifloxacin hydrochloride) intravenous solutions are indicated for treatment of adults with severe and complicated skin and skin structure infections who require initial parenteral therapy, and who have intolerance to alternative agents. (especially penicillin allergy), and when caused by organisms known to be susceptible to moxifloxacin. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with moxifloxacin may be initiated. in some conditions, before results of these tests are known. once results become available, therapy should be continued with the most appropriate antibiotic therapy.

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome s.a. - dolutegravir (dolutegravir sodium), abacavir (abacavir sulfate), lamivudine - tablets film-coated - 50mg+ 600mg+ 300mg

Израел - английски - Ministry of Health

glaxo smith kline (israel) ltd - lamivudine - film coated tablets - lamivudine 300 mg - lamivudine - lamivudine - epivir is indicated as part of antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected adults and children. 28/10/2018 בקשה לשינוי משטר מינון

САЩ - английски - NLM (National Library of Medicine)

orient pharma co., ltd. - miglitol (unii: 0v5436jaqw) (miglitol - unii:0v5436jaqw) - miglitol 25 mg - miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. miglitol tablets are contraindicated in patients with: - diabetic ketoacidosis - inflammatory bowel disease, colonic ulceration, or partial intestinal obstruction, and in patients predisposed to intestinal obstruction - chronic intestinal diseases associated with marked disorders of digestion or absorption, or with conditions that may deteriorate as a result of increased gas formation in the intestine - hypersensitivity to the drug or any of its components

САЩ - английски - NLM (National Library of Medicine)

sun pharmaceutical industries inc. - miglitol (unii: 0v5436jaqw) (miglitol - unii:0v5436jaqw) - miglitol 25 mg - miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. miglitol tablets are contraindicated in patients with:

Армения - английски - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome s.a. - abacavir (abacavir sulfate), lamivudine - tablets film-coated - 600mg+ 300mg

Австралия - английски - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 384.8 mg - tablet, enteric coated - excipient ingredients: crospovidone; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide red; hypromellose phthalate; iron oxide yellow; povidone; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 192.4 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose phthalate; maize starch; indigo carmine; povidone; titanium dioxide; magnesium stearate; crospovidone; iron oxide yellow; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Австралия - английски - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - fexofenadine hydrochloride, quantity: 30 mg - tablet, film coated - excipient ingredients: titanium dioxide; pregelatinised maize starch; hypromellose; macrogol 400; colloidal anhydrous silica; magnesium stearate; povidone; microcrystalline cellulose; croscarmellose sodium; iron oxide red; iron oxide yellow - relief of symptoms associated with seasonal allergic rhinitis, allergic rhinitis or urticaria in adults and children from 6 years of age.

Израел - английски - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate; lamivudine - film coated tablets - abacavir as sulfate 600 mg; lamivudine 300 mg - kivexa is a fixed-dose combination of two nucleoside analogues (abacavir and lamivudine). it is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.28/10/2018 עדכון התוויה: kivexa is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and, adolescents s of and children weighing at least 25 kg.שינוי משטר מינון:adults, adolescents and children weighing at least 25 kg:the recommended dose of kivexa is one tablet once daily.children under 25 kg: kivexa should not be administered children who weigh less than 25 kg because it is a fixed dose tablet that cannot be dose reduced.paediatric population: the safety and efficacy of kivexa in children weighing less than 25 kg has not been established. currently available data are described in section 4.8, 5.1 and 5.2 but no recommendation on posology can be made.